nach oben

Erschienen in:

11.02.2020 | Original Paper

Understanding PrEP Persistence: Provider and Patient Perspectives

verfasst von: Nicole D. Laborde, Patrick M. Kinley, Matthew Spinelli, Eric Vittinghoff, Ryan Whitacre, Hyman M. Scott, Susan P. Buchbinder

Erschienen in: AIDS and Behavior | Ausgabe 9/2020

Einloggen, um Zugang zu erhalten

Abstract

PrEP persistence, or PrEP use over time, has been shown to be short, with most PrEP users stopping within 6–12 months. Furthermore, those most vulnerable to HIV often use PrEP for shorter periods. This qualitative study explores patient, provider, and contextual factors that influence PrEP persistence. In interviews with 25 PrEP users and 18 PrEP providers in San Francisco’s safety net clinics, we analyze the perceived benefits and difficulties of taking PrEP, including structural barriers. We identify different steps in receipt of PrEP care (clinic visits and lab tests, pharmacy interactions, and medication adherence), and describe barriers and facilitators for providers and patients at each step. Our findings suggest that drop-in visits, streamlined testing, standing orders for labs, and 90-day PrEP prescriptions are highly desirable for many PrEP users. Also important are the proactive provision of adherence support and counseling, and referrals for housing, substance use, and mental health services.

Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820–9. https://doi.org/10.1016/s1473-3099(14)70847-3.PubMedPubMedCentralCrossRef

Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. NEngl J Med. 2010;363(27):2587–99.CrossRef

McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. The Lancet. 2016;387(10013):53–60. https://doi.org/10.1016/s0140-6736(15)00056-2.CrossRef

Bae JW, Guyer W, Grimm K, Altice FL. Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research. AIDS. 2011;25(3):279–90. https://doi.org/10.1097/QAD.0b013e328340feb0.PubMedCrossRef

Cramer J, Roy A, Burrell A, Fairchild C, Fuldeore M, Ollendorf D, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11:44–7.CrossRefPubMed

Spinelli MA, Scott HM, Vittinghoff E, Liu AY, Gonzalez R, Morehead-Gee A, et al., editors. Missed Visits associated with future preexposure prophylaxis (PrEP) discontinuation among PrEP users in a municipal primary care health network. Open forum infectious diseases. Oxford: Oxford University Press; 2019.

Blackstock OJ, Patel VV, Felsen U, Park C, Jain S. Pre-exposure prophylaxis prescribing and retention in care among heterosexual women at a community-based comprehensive sexual health clinic. AIDS Care. 2017;29(7):866–9. https://doi.org/10.1080/09540121.2017.1286287.PubMedPubMedCentralCrossRef

Krakower D, Maloney KM, Powell VE, Levine K, Grasso C, Melbourne K, et al. Patterns and clinical consequences of discontinuing HIV preexposure prophylaxis during primary care. J Int AIDS Soc. 2019;22(2):e25250.PubMedPubMedCentralCrossRef

Liu A. Learning from Oral PrEP care retention: rates, patterns, and interventions. NIAID-NIMH behavioral and social science meeting; May 13–14, 2019.

10.

Rusie LK, Orengo C, Burrell D, Ramachandran A, Houlberg M, Keglovitz K, et al. Preexposure prophylaxis initiation and retention in care over 5 years, 2012–2017: are quarterly visits too much? Clin Infect Dis. 2018;67(2):283–7. https://doi.org/10.1093/cid/ciy160.PubMedPubMedCentralCrossRef

11.

van Epps P, Maier M, Lund B, Howren MB, Beck B, Beste L, et al. Medication adherence in a nationwide cohort of veterans initiating pre-exposure prophylaxis (PrEP) to prevent HIV infection. J Acquir Immune Defic Syndr. 2018;77(3):272–8.PubMedCrossRef

12.

Zucker J, Carnevale C, Richards P, Slowikowski J, Borsa A, Gottlieb F, et al. Predictors of disengagement in care for individuals receiving pre-exposure prophylaxis (PrEP). J Int AIDS Soc. 2019. https://doi.org/10.1097/qai.0000000000002054.CrossRef

13.

Chan PA, Mena L, Patel R, Oldenburg CE, Beauchamps L, Perez-Brumer AG, et al. Retention in care outcomes for HIV pre-exposure prophylaxis implementation programmes among men who have sex with men in three US cities. J Int AIDS Soc. 2016;19(1):20903. https://doi.org/10.7448/ias.19.1.20903.PubMedPubMedCentralCrossRef

14.

Dombrowski JC, Golden MR, Barbee LA, Khosropour CM. Patient disengagement from an HIV preexposure prophylaxis program in a sexually transmitted disease clinic. Sex Transm Dis. 2018;45(9):e62–e6464.PubMedPubMedCentralCrossRef

15.

Scott H, Spinelli MA, Vittinghoff E, Morehead-Gee A, Nordell M, Liu A, et al. Racial/Ethnic and HIV risk category disparities in PrEP discontinuation among patients in publicly-funded primary care clinics. AIDS. 2019;33(14):2189–2195.PubMedCrossRef

16.

Greenwald Z, Beauchemin M, Benomar K, Landry G, Boissonnault M, Charest L, et al., editors. High seroconversion rates following prep discontinuance in a Montreal clinic. Boston, MA: CROI; 2018.

17.

SFDPH. Ask about PrEP: How providers can prescribe PrEP to prevent HIV and reduce health disparities; 2017.

18.

Spinelli MA, Scott HM, Vittinghoff E, Liu AY, Morehead-Gee A, Gonzalez R, et al., editors. Provider adherence to pre-exposure prophylaxis monitoring guidelines in a large primary care network. Open forum infectious diseases. Oxford: Oxford University Press; 2018.

19.

CDC. Preexposure prophylaxis for the prevention of HIV infection in the United States—2017 update.

20.

Parsons JT, Rendina HJ, Lassiter JM, Whitfield THF, Starks TJ, Grov C. Uptake of HIV pre-exposure prophylaxis (PrEP) in a national cohort of gay and bisexual men in the United States. J Acquir Immune Defic Syndr. 2017;74(3):285–92. https://doi.org/10.1097/qai.0000000000001251.PubMedPubMedCentralCrossRef

21.

Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77–101. https://doi.org/10.1191/1478088706qp063oa.CrossRef

22.

Philbin MM, Parker CM, Parker RG, Wilson PA, Garcia J, Hirsch JS. The promise of pre-exposure prophylaxis for black men who have sex with men: an ecological approach to attitudes, beliefs, and barriers. AIDS Patient Care STDs. 2016;30(6):282–90. https://doi.org/10.1089/apc.2016.0037.PubMedPubMedCentralCrossRef

23.

Hughes SD, Sheon N, Andrew EVW, Cohen SE, Doblecki-Lewis S, Liu AY. Body/selves and beyond: Men’s narratives of sexual behavior on PrEP. Med Anthropol. 2018;37(5):387–400. https://doi.org/10.1080/01459740.2017.1416608.PubMedPubMedCentralCrossRef

24.

Gafos M, Horne R, Nutland W, Bell G, Rae C, Wayal S, et al. The context of sexual risk behaviour among men who have sex with men seeking PrEP, and the impact of PrEP on sexual behaviour. AIDS Behav. 2019;23(7):1708–20. https://doi.org/10.1007/s10461-018-2300-5.PubMedCrossRef

25.

Kelley CF, Kahle E, Siegler A, Sanchez T, del Rio C, Sullivan PS, et al. Applying a PrEP continuum of care for men who have sex with men in Atlanta, Georgia. Clin Infect Dis. 2015;61(10):1590–7.PubMedPubMedCentralCrossRef

26.

Serota DP, Rosenberg ES, Lockard AM, Rolle C-PM, Luisi N, Cutro S, et al. Beyond the biomedical: preexposure prophylaxis failures in a cohort of young black men who have sex with men in Atlanta, Georgia. Clin Infect Dis. 2018;67(6):965–70. https://doi.org/10.1093/cid/ciy297PubMedPubMedCentralCrossRef

27.

Laborde ND, Spinelli MA, Scott H, editors. Uncomfortable conversations: sexual health disparities in identifying PrEP candidates. San Jose, CA: American Anthropological Association; 2018.

28.

Lankowski AJ, Bien-Gund CH, Patel VV, Felsen UR, Silvera R, Blackstock OJJA, et al. PrEP in the real world: predictors of 6-month retention in a diverse urban cohort. AIDS Behav. 2019;23(7):1797–802. https://doi.org/10.1007/s10461-018-2296-x.PubMedPubMedCentralCrossRef

29.

Lancki N, Almirol E, Alon L, McNulty M, Schneider JA. Preexposure prophylaxis guidelines have low sensitivity for identifying seroconverters in a sample of young black MSM in Chicago. AIDS. 2018;32(3):383–92.PubMed

30.

Golub S, editor. PrEP messaging: taking “Risk” out of the pitch. HIVR4P; Madrid; 2018.

31.

Calabrese SK, Underhill K. How stigma surrounding the use of HIV preexposure prophylaxis undermines prevention and pleasure: a call to destigmatize “truvada whores”. Am J Public Health. 2015;105(10):1960–4.PubMedPubMedCentralCrossRef

32.

Calabrese SK, Earnshaw VA, Underhill K, Hansen NB, Dovidio JF. The impact of patient race on clinical decisions related to prescribing HIV pre-exposure prophylaxis (PrEP): assumptions about sexual risk compensation and implications for access. AIDS Behav. 2014;18(2):226–40. https://doi.org/10.1007/s10461-013-0675-xPubMedPubMedCentralCrossRef

33.

Millett GA, Flores SA, Peterson JL, Bakeman R. Explaining disparities in HIV infection among black and white men who have sex with men: a meta-analysis of HIV risk behaviors. AIDS. 2007;21(15):2083–91.PubMedCrossRef

34.

Mimiaga MJ, Reisner SL, Cranston K, Isenberg D, Bright D, Daffin G, et al. Sexual mixing patterns and partner characteristics of black MSM in Massachusetts at increased risk for HIV infection and transmission. J Urban Health. 2009;86(4):602–23.PubMedPubMedCentralCrossRef

35.

Maulsby C, Millett G, Lindsey K, Kelley R, Johnson K, Montoya D, et al. HIV among black men who have sex with men (MSM) in the United States: a review of the literature. AIDS Behav. 2014;18(1):10–25.PubMedCrossRef

36.

Sullivan PS, Peterson J, Rosenberg ES, Kelley CF, Cooper H, Vaughan A, et al. Understanding racial HIV/STI disparities in black and white men who have sex with men: a multilevel approach. PLoS ONE. 2014;9(3):e90514.PubMedPubMedCentralCrossRef

37.

Irvin R, Vallabhaneni S, Scott H, Williams JK, Wilton L, Li X, et al. Examining levels of risk behaviors among black men who have sex with Men (MSM) and the association with HIV acquisition. PLoS ONE. 2015;10(2):e0118281.PubMedPubMedCentralCrossRef

38.

Sullivan PS, Rosenberg ES, Sanchez TH, Kelley CF, Luisi N, Cooper HL, et al. Explaining racial disparities in HIV incidence in black and white men who have sex with men in Atlanta, GA: a prospective observational cohort study. Ann Epidemiol. 2015;25(6):445–54.PubMedPubMedCentralCrossRef

39.

Calabrese SK, Krakower DS, Mayer KH. Integrating HIV preexposure prophylaxis (PrEP) into routine preventive health care to avoid exacerbating disparities. Am J Public Health. 2017;107(12):1883–9. https://doi.org/10.2105/ajph.2017.304061.PubMedPubMedCentralCrossRef

40.

Stekler JD, McMahan V, Ballinger L, Viquez L, Swanson F, Stockton J, et al. HIV pre-exposure prophylaxis prescribing through telehealth. JAIDS J Acquir Immune Defic Syndr. 2018;77(5):e40–e4242.PubMedCrossRef

41.

Touger R, Wood BR. A review of telehealth innovations for HIV pre-exposure prophylaxis (PrEP). Curr HIV/AIDS Rep. 2019;16(1):113–9.PubMedCrossRef

42.

Liu AY, Vittinghoff E, von Felten P, Rivet Amico K, Anderson PL, Lester R, et al. Randomized controlled trial of a mobile health intervention to promote retention and adherence to preexposure prophylaxis among young people at risk for human immunodeficiency virus: The EPIC Study. Clin Infect Dis. 2019;68(12):2010–7.PubMedCrossRef

43.

Getz L. Texting for Help. Social Work Today. 2014;14(4).

Titel: Understanding PrEP Persistence: Provider and Patient Perspectives
verfasst von: Nicole D. Laborde
Patrick M. Kinley
Matthew Spinelli
Eric Vittinghoff
Ryan Whitacre
Hyman M. Scott
Susan P. Buchbinder
Publikationsdatum: 11.02.2020
Verlag: Springer US
Erschienen in: AIDS and Behavior / Ausgabe 9/2020
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI: https://doi.org/10.1007/s10461-020-02807-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Hereditäres Angioödem: Tablette könnte Akuttherapie erleichtern

05.06.2024 Hereditäres Angioödem Nachrichten

Medikamente zur Bedarfstherapie bei hereditärem Angioödem sind bisher nur als Injektionen und Infusionen verfügbar. Der Arzneistoff Sebetralstat kann oral verabreicht werden und liefert vielversprechende Daten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2020

Influences on Adherence to Antiretroviral Therapy (ART) in Early-Stage HIV Disease: Qualitative Study from Uganda and South Africa

COVID-19 Policies can Perpetuate Violence Against Transgender Communities: Insights from Peru

Sex Work as a Mediator Between Female Gender and Incident HIV Infection Among People Who Inject Drugs in Tijuana, Mexico

From HIV to Coronavirus: AIDS Service Organizations Adaptative Responses to COVID-19, Birmingham, Alabama

COVID-19-Compliant Strategies for Supporting Treatment Adherence Among People Living with HIV in Sub-Saharan Africa